Halozyme Therapeutics | HALO - Current Assets


Halozyme Therapeutics reported $1.33B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Agios Pharmaceuticals USD 1.03B 13.64M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amarin USD 628.33M 21.52M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
Baxter International USD 6.93B 184M Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Halozyme Therapeutics USD 1.33B 206.08M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
MannKind USD 358.84M 79.81M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
United Therapeutics USD 3.49B 332.9M Sep/2025